Target intelligence / Profile preview

Wall teichoic acid (WTA)

Target
WTA
Molecular classification
Bacterial cell wall glycopolymer, Virulence factor, Surface antigen, Anionic glycopolymer
01

Overview

Wall teichoic acids (WTAs) are anionic glycopolymers covalently attached to the peptidoglycan layers of Gram-positive bacteria, often accounting for a significant portion of the total cell wall mass. They play essential roles in bacterial physiology, including the maintenance of cell shape, regulation of cell division (septal placement), and ion homeostasis by binding divalent cations like Mg2+ and Ca2+. Beyond structural functions, WTAs are critical virulence factors that facilitate host colonization and biofilm formation while shielding the bacteria from host defenses such as cationic antimicrobial peptides. In pathogens like methicillin-resistant Staphylococcus aureus (MRSA), WTAs are vital for the expression of high-level resistance to beta-lactam antibiotics. Therapeutic strategies focus on inhibiting the WTA biosynthesis pathway (e.g., targeting enzymes like TarO or TarG), which can lead to bacterial growth arrest or resensitize resistant strains to existing antibiotics. WTAs also serve as key surface antigens recognized by the immune system and bacteriophages, making them attractive targets for vaccines and monoclonal antibody therapies.

Other names
WTAWall teichoic acidsTeichoic acidAnionic cell wall glycopolymerPoly(ribitol phosphate)Poly(glycerol phosphate)
02

Mechanism of action

Inhibition of biosynthesis enzymes (e.g., TarO, TarA, TarG) to disrupt cell wall assembly, attenuate virulence, and restore sensitivity to beta-lactam antibiotics.

03

Biological functions

Cell wall integrityRegulation of cell divisionIon homeostasisHost colonizationBiofilm formationImmune evasionPhage receptorToxin release facilitation
04

Disease associations

Bacterial infectionMethicillin-resistant Staphylococcus aureus (MRSA) infectionSepsisInfectious keratitisBiofilm-related infection
05

Safety considerations

Host toxicity (e.g., tunicamycin inhibits eukaryotic N-glycosylation)High frequency of resistance mutations in late-stage targets like TarGInduction of cell wall stress responsesBacterial compensatory mechanisms
06

Interacting drugs

Tunicamycin

5 more in the full profile.

07

Biomarkers

WTA glycotype (alpha/beta-GlcNAc modification)tar gene expression levelsBacterial loadPhage susceptibility

Beyond the preview

Go deeper on Wall teichoic acid (WTA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wall teichoic acid (WTA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call